Noticias

Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.

Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.

The telehealth company posted a net loss of $92 million in the first quarter as its shift away from compounded weight loss drugs drove up costs

Trump’s China summit threatens the AI boom, Ford gets into the energy storage business, Hims & Hers posts a surprise loss, and more news to start your day.

Intel and Micron shares falls as investors opt to lock in profits following a breakneck rally in chip stocks.

↗️ Venture Global (VG): The liquefied-natural-gas exporter, which stands to benefit from the closure of the Strait of Hormuz, is due to report results this morning, potentially shedding light on the strength of demand.

Despite restructuring costs, Hims & Hers Health Inc (HIMS) reports robust international growth and raises 2026 revenue outlook.

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bronstein, Gewirtz & Grossman, LLC has launched a legal investigation into Hims & Hers Health's corporate practices. The probe focuses on potential wrongdoing by certain officers and directors relating to events before April 2025. The review is aimed at assessing possible impacts on shareholder interests and corporate governance at NYSE:HIMS. For investors watching Hims & Hers Health, NYSE:HIMS, the new legal investigation arrives after a period of sharp share price moves. The stock closed...

The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.

Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.

Shares of Hims & Hers Health sank late Monday after the company underperformed first-quarter earnings and revenue expectations, surprising Wall Street with a quarterly loss. The telehealth provider, which made a name for itself in the business of weight-loss drugs, posted a first-quarter loss of 40 cents a share, compared with profit of 20 cents a share a year ago. Wall Street was looking for a profit of 3 cents a share.

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $690 million at the midpoint, or 6% above analysts’ estimates. Its GAAP loss of $0.40 per share was significantly below analysts’ consensus estimates.

HIMS broadens its digital health platform with Labs, menopause and testosterone care, global acquisitions and a Novo Nordisk GLP-1 tie-up.

Markets Await Key Inflation Data This Week.

We'll see new inflation data the same week the Senate is likely to confirm Kevin Warsh - an advocate of cutting interest rates - as Fed Chair.

The benchmark US stock measures were pointing lower before the opening bell Monday as the US rejecte

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

This week is peppered with potential market-moving events. Headlining are Tuesday’s inflation report, which will offer the latest glimpse of how the Iran war is affecting consumer prices, and President Trump’s long-awaited—and delayed—visit to China, with the war and tariffs likely to be central topics.